NEW YORK, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Endo International plc (“ENDP” or the “Company”) (Nasdaq:ENDP) in the United States District Court for the Southern District of New York on behalf of purchasers of common stock of Endo between September 28, 2015 and November 2, 2016, inclusive (the “Class Period”).
According to the Complaint, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s subsidiary, Par Pharmaceutical, colluded with several of its industry peers to fix generic drug prices; (2) this conduct constituted a violation of federal antitrust laws; (3) Endo’s revenues during the Class Period were partially the result of illegal conduct; and (4) as a result of the above, the Company’s public statements were materially false and misleading at all relevant times.
On November 3, 2016, Bloomberg News reported that the United States Justice Department is conducting an antitrust investigation of over a dozen companies, including Par Pharmaceutical, to determine whether they unlawfully colluded with each other to fix generic drug prices. When this news was announced, shares of Endo fell in value, causing investors harm.
If you wish to serve as lead plaintiff, you must move the Court no later than January 6, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at tjmckenna@gme-law.com or gegleston@gme-law.com.
Please visit our website at http://www.gme-law.com for more information about the firm.